STAT August 2, 2024
Andrew Joseph

LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, extending the power of immunotherapies to difficult-to-reach sarcomas.

The medicine, called Tecelra and developed by Adaptimmune Therapeutics, is what’s known as a T cell receptor therapy. The approach has similarities to the CAR-T therapies that have dramatically improved the treatment of some blood cancers, but it has tricks...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency

Share This Article